Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Lord

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Microbiome|May 30, 2026
Remodelling of cystic fibrosis respiratory microbiota in response to extended elexacaftor-tezacaftor-ivacaftor therapyHelen Gavillet, Lauren R Hatfield, Michelle Hardman, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|May 14, 2025
Managing an ageing cystic fibrosis population: challenges and prioritiesFreddy J Frost, Daniel G Peckham, Imogen C Felton, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2010
Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge regionYu Mi Ahn, Michael Clare, Carol L Ensinger, et al.
Nature Communications|September 17, 2022
Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myelomaYandan Yang, Arnold Bolomsky, Thomas Oellerich, et al.
Cancer Cell|April 13, 2011
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036Wayne W Chan, Scott C Wise, Michael D Kaufman, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Microbiome|May 30, 2026
Remodelling of cystic fibrosis respiratory microbiota in response to extended elexacaftor-tezacaftor-ivacaftor therapyHelen Gavillet, Lauren R Hatfield, Michelle Hardman, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|May 14, 2025
Managing an ageing cystic fibrosis population: challenges and prioritiesFreddy J Frost, Daniel G Peckham, Imogen C Felton, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2010
Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge regionYu Mi Ahn, Michael Clare, Carol L Ensinger, et al.
Nature Communications|September 17, 2022
Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myelomaYandan Yang, Arnold Bolomsky, Thomas Oellerich, et al.
Cancer Cell|April 13, 2011
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036Wayne W Chan, Scott C Wise, Michael D Kaufman, et al.
Pageof 7